Boston Scientific (NYSE:BSX – Get Free Report) is projected to release its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Boston Scientific to announce earnings of $0.7230 per share and revenue of $5.06 billion for the quarter. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. On average, analysts expect Boston Scientific to post $3.24 EPS for the current fiscal year and $3.36 EPS for the next fiscal year.
Boston Scientific Stock Down 0.0%
BSX stock opened at $45.67 on Monday. The stock has a market capitalization of $66.19 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific has a 12 month low of $41.38 and a 12 month high of $105.65. The firm has a 50-day moving average price of $45.46 and a 200-day moving average price of $49.06.
Analyst Upgrades and Downgrades
BSX has been the topic of several research reports. Wells Fargo & Company decreased their price target on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating on the stock in a report on Wednesday, September 23rd. Royal Bank Of Canada dropped their price objective on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, July 30th. Needham & Company LLC cut their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Boston Scientific in a research note on Friday, October 2nd. Finally, TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a report on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $68.23.
Read Our Latest Stock Report on Boston Scientific
Insider Buying and Selling at Boston Scientific
In other news, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by company insiders.
About Boston Scientific
Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.
Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.
Further Reading
- Five stocks we like better than Boston Scientific
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
